로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > KIR2DL1

KIR2DL1

요약

Name:Killer cell immunoglobulin-like receptor 2DL1
Target Synonym:KIR2DL1,NKAT-1,NKAT1,MHC class I NK cell receptor,Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1,Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 1,P58 Natural Killer Cell Receptor Clones CL-42/47.11,P58 Killer Cell Inhibitory Receptor KIR-K64,Natural Killer-Associated Transcript 1,P58.1 MHC Class-I-Specific NK Receptor,CD158 Antigen-Like Family Member A,P58 NK Receptor CL-42/47.11,CD158A,Killer Cell Immunoglobulin-Like Receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
KI1-H5255 Human Human KIR2DL1 / CD158a / NKAT-1 Protein, Fc Tag
KI1-H5255-structure
KI1-H5255-sds

일부의 생물활성 데이터

KI1-H5255-ELISA
 KIR2DL1 ELISA

Immobilized Human KIR2DL1, Fc Tag (Cat. No. KI1-H5255) at 1 μg/mL (100 μL/well) can bind Lirilummab with a linear range of 0.1-8 ng/mL (QC tested).

Synonym Name

CD158a

Background

Killer cell immunoglobulin-like receptor 2DL1(KIR2DL1), which belongs to the immunoglobulin superfamily, is an inhibitory receptor of NK cells. Regulation of NK cell activity is mediated through killer-cell immunoglobulin-like receptors (KIR) ability to recognize human leukocyte antigen (HLA) class I molecules as ligands. Interaction of KIR and HLA is implicated in viral infections, autoimmunity, and reproduction and there is growing evidence of the coevolution of these two independently segregating gene families. Association of KIR2DL1 with β-arrestin 2 mediated recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to KIR2DL1 and facilitated downstream inhibitory signaling.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Bone Marrow Neoplasms; Squamous Cell Carcinoma of Head and Neck; Smoldering Multiple Myeloma; Neoplasms; Multiple Myeloma; Urinary Bladder Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute Details

This web search service is supported by Google Inc.

totop